

NashvillePost

AREA STOCKS

Cumberland Pharmaceuticals stock soars

Company sees highest share value since 2022 following positive results from heart disease drug trial

HANNAH HERNER FEB 4, 2025

(Editor's note: This article has been updated since its publication.)

Cumberland Pharmaceuticals saw its shares pop Tuesday, finishing the trading day up 76 percent on heavy volume following positive results from a trial for a heart disease drug.

The stock of the Nashville-based drug company (ticker: **CPIX**) concluded the day priced at \$3.76, up \$1.63 per share (the equivalent increase of 76.5 percent). The price per share is the highest since 2022.

Approximately 18 million Cumberland Pharmaceuticals changed ownership hands for the day, according to Yahoo Finance. On average and for the past 30 days, about 2.04 million shares have traded daily.

Cumberland Pharmaceuticals recently reported positive top line results for its Phase 2 trial on ifetroban, an oral therapy for Duchenne muscular dystrophy (DMD) heart disease, the leading cause of death in people with DMD.

The results build on a 2019 Vanderbilt University Medical Center trial that found ifetroban is protective against cardiomyopathy. There are no drugs targeting DMD-related heart disease, according to the press release, as the company is focusing efforts on products for rare diseases.

“These results represent a significant milestone in DMD cardiomyopathy,” Larry Markham, professor of pediatrics and medicine at Indiana University School of Medicine and principal investigator of the FIGHT DMD trial, said in a release.

“We are seeing evidence that there is an opportunity to potentially alter the course of heart disease in DMD patients. The improvement in cardiac function observed with ifetroban, particularly in the high-dose group, offers hope for these patients and their families.”

Relatedly, Cumberland Pharmaceuticals also saw **a nearly 100 percent uptick in share value** in December, following the announcement of Food and Drug Administration approval of a new drug application for acetadote, an intravenous formulation that can prevent or lessen liver injury after a person ingests potentially toxic quantities of acetaminophen.